Sun Pharma comes up with psoriasis treatment drug ‘ILUMYA’ in US

24 Oct 2018 Evaluate

Sun Pharmaceutical Industries has launched its plaque psoriasis treatment drug ‘ILUMYA’ (tildrakizumab-asmn) 100 mg/mL in the United States. ILUMYA is an injectable interleukin-23 (IL-23) inhibitor approved by the USFDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ILUMYA injections are administered by a healthcare provider every 12 weeks, following starter doses at Week 0 and Week 4.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1680.40 11.20 (0.67%)
19-Jan-2026 14:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1680.40
Dr. Reddys Lab 1171.45
Cipla 1396.20
Zydus Lifesciences 880.40
Lupin 2175.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×